Floatz logo

Emapalumab

Primary Mediastinal Large B-cell Lymphoma

Marcela V. Maus, M.D.,Ph.D.monoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

86 Active assets in the Primary Mediastinal Large B-cell Lymphoma cohort.

Asset / SponsorPhaseRating
Ifosfamide
David Bond, MD
Phase 4BBB
Inno-206
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 4BBB
ETOPOSIDE
University of Washington
Phase 4BBB
Inno-206
University of Washington
Phase 4BBB
ETOPOSIDE
University of Washington
Phase 4BBB

View all 50 →

Same molecule, other indications

Emapalumab is also rated in:

non-Hodgkin lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
Refractory Non-Hodgkin LymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
large B-cell lymphomaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →